BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 16934487)

  • 1. The Myc oncoprotein as a therapeutic target for human cancer.
    Vita M; Henriksson M
    Semin Cancer Biol; 2006 Aug; 16(4):318-30. PubMed ID: 16934487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer therapeutics: targeting the dark side of Myc.
    Ponzielli R; Katz S; Barsyte-Lovejoy D; Penn LZ
    Eur J Cancer; 2005 Nov; 41(16):2485-501. PubMed ID: 16243519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translocations involving c-myc and c-myc function.
    Boxer LM; Dang CV
    Oncogene; 2001 Sep; 20(40):5595-610. PubMed ID: 11607812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mnt takes control as key regulator of the myc/max/mxd network.
    Wahlström T; Henriksson M
    Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.
    Pelengaris S; Khan M
    Expert Opin Ther Targets; 2003 Oct; 7(5):623-42. PubMed ID: 14498825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
    Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
    Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proto-oncogene c-myc in hematopoietic development and leukemogenesis.
    Hoffman B; Amanullah A; Shafarenko M; Liebermann DA
    Oncogene; 2002 May; 21(21):3414-21. PubMed ID: 12032779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME; Lemieux R; Jung D
    J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proto-oncogene c-myc and apoptosis.
    Hoffman B; Liebermann DA
    Oncogene; 1998 Dec; 17(25):3351-7. PubMed ID: 9916997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Myc as a therapeutic target in cancer.
    Prochownik EV
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):289-302. PubMed ID: 15056059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
    Lin CJ; Malina A; Pelletier J
    Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functions of myc:max in the control of cell proliferation and tumorigenesis.
    Hurlin PJ; Dezfouli S
    Int Rev Cytol; 2004; 238():183-226. PubMed ID: 15364199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alpha1 subunit of GABAA receptor is repressed by c-myc and is pro-apoptotic.
    Vaknin UA; Hann SR
    J Cell Biochem; 2006 Apr; 97(5):1094-103. PubMed ID: 16294320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic enzymes regulated by the Myc oncogene are possible targets for chemotherapy or chemoprevention.
    Rimpi S; Nilsson JA
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):305-10. PubMed ID: 17371266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
    Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
    Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
    Verheul HM; Qian DZ; Carducci MA; Pili R
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells.
    Lin CP; Liu JD; Chow JM; Liu CR; Liu HE
    Anticancer Drugs; 2007 Feb; 18(2):161-70. PubMed ID: 17159602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy.
    Larsson LG; Henriksson MA
    Exp Cell Res; 2010 May; 316(8):1429-37. PubMed ID: 20382143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of c-myc in cellular growth control.
    Schmidt EV
    Oncogene; 1999 May; 18(19):2988-96. PubMed ID: 10378694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The c-myc promoter: still MysterY and challenge.
    Wierstra I; Alves J
    Adv Cancer Res; 2008; 99():113-333. PubMed ID: 18037408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.